Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic

Abstract

Background. The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and Methods. A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The

Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource‐limited setting amid the COVID‐19 pandemic

“…14 So, the cancer treatment needs to be delivered on time with safe and feasible adaptive measures. 12 We observed that IE can be given with 100% success in the outpatient department in pediatric patients with EWS in a resource-limited setting and inpatient admissions can be averted and these beds can be saved for the COVID-19 patients.…”

“…Pediatric cancer care has been considerably affected by the COVID‐19 pandemic 11 . The major concern for cancer patients is the inability to receive necessary cancer treatment on time 12 . It has led to an increased burden on inpatient hospital beds and significant delays in cancer treatment, resulting in poorer disease outcomes and exhaustion of health care services 10 .…”

“…reported that up to 30% of cancer patients had modifications in their treatment during the COVID‐19 pandemic 14 . So, the cancer treatment needs to be delivered on time with safe and feasible adaptive measures 12 …”

“… 11 The major concern for cancer patients is the inability to receive necessary cancer treatment on time. 12 It has led to an increased burden on inpatient hospital beds and significant delays in cancer treatment, resulting in poorer disease outcomes and exhaustion of health care services. 10 Edge R showed that 42% of cancer patients and survivors reported some level of disruption to their cancer treatment.…”

“… 14 So, the cancer treatment needs to be delivered on time with safe and feasible adaptive measures. 12 …”